1. China Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Hinova Pharmaceuticals, Inc. Class A

Hinova Pharmaceuticals, Inc. Class A

SSSE:688302
28.68
CNY
+1.00
(+3.61%)
-1.25EPS
3.48BMarket Cap
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.04
0.04
- -
- -
0.02
- -
- -
0.21
0.66
Basic EPS, GAAP
-0.39
-1.13
-6.97
-4.12
-3.32
-2.97
-2.01
-1.39
-1.25
Free Cash Flow per Basic Share
-0.2
-0.83
-3.5
-3.33
-4.23
-3.58
-2.79
-1.94
- -
Dividend per Share
- -
- -
0.01
0.03
0.04
0.01
- -
0.01
0.02
Book Value per Share
0.28
-0.49
13.28
7.97
16.01
13.81
12.04
10.74
10.17
Tangible Book Value per Share
0.28
-0.49
13.28
7.97
15.69
13.49
11.73
10.43
9.86
Basic Weighted Avg Shares
99
99
70
74
91
99
99
99
99
Sales/Revenue/Turnover
4
4
- -
- -
2
- -
- -
20
65
Operating Margin (%)
-1,110.24
-2,638.92
- -
- -
-20,456.66
- -
-60,789.31
-768.72
-211.74
Depreciation Expense
1
1
1
3
5
6
6
7
- -
Net Income, GAAP
-39
-112
-490
-306
-302
-294
-199
-137
-124
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-1,083.09
-2,642.93
- -
- -
-18,264.52
- -
-54,382.77
-670.51
-190.14
Working Capital
16
-41
983
764
1,473
1,040
739
780
718
LT Debt
- -
- -
- -
1
3
9
6
103
102
Total Equity
21
-36
986
789
1,585
1,367
1,192
1,064
1,007
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
-34.5
-25.4
-19.93
-15.59
-12.17
-11.43

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
3
3
3
LT Borrowings
100
100
100
LT Finance Leases
3
2
2
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
99
99
99
Market Capitalization
4,869
4,359
3,482

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
906
881
856
Cash, Cash Equivalents & STI
749
828
785
Accounts Receivable, Net
- -
3
12
Inventories
3
5
15
Total Current Liabilities
126
125
139
Payables & Accruals
- -
- -
- -
ST Debt
3
3
3
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
8.73%
-10.79%
Free Cash Flow
- -
-0.93%
-30.68%
Net Income, GAAP
- -
-20.97%
-31.2%
Sales/Revenue/Turnover
- -
- -
5,480.11%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
13
- -
-3
20
2026
26
29
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.48
-0.54
-0.54
-0.46
-2.01
2025
-0.32
-0.3
- -
-0.38
-1.39
2026
-0.3
-0.27
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
0.01
0.01
2026
0.01
0.01
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Yuan Wei Chen
Full Time Employees
241
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Chengdu China
IPO Date
Apr 12, 2022
Website
hinovapharma.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Hinova Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative small-molecule therapeutics and targeted protein degraders for the treatment of oncology and metabolic diseases. Founded in 2013 and headquartered in Chengdu, China, the company operates research, development, and clinical management facilities across Chengdu, Beijing, and the United States. Hinova Pharmaceuticals leverages proprietary drug discovery engines, including a targeted protein degradation (PROTAC) platform and a deuterated drug technology platform. The company's therapeutic pipeline comprises HC-1119, an oral deuterated androgen receptor antagonist developed for metastatic castration-resistant prostate cancer (mCRPC); HP518, an orally bioavailable PROTAC androgen receptor degrader targeting advanced and drug-resistant prostate cancer; HP501, a selective uric acid transporter 1 (URAT1) inhibitor indicated for hyperuricemia and gout; HP551, a next-generation URAT1 inhibitor for metabolic conditions; HP537, a selective p300/CBP histone acetyltransferase inhibitor evaluated for solid tumors and hematological malignancies; and HP560, an oral PROTAC estrogen receptor degrader developed for ER-positive and HER2-negative breast cancer. In recent developments, Hinova Pharmaceuticals submitted a New Drug Application (NDA) to China's National Medical Products Administration (NMPA) for its lead oncology asset HC-1119; accelerated multi-regional Phase I/II clinical trials for HP518 across China, the United States, and Australia following international regulatory clearances; advanced Phase II clinical trials for HP501 in gout and hyperuricemia; and expanded its strategic collaborations and clinical-stage manufacturing infrastructure to support global pipeline commercialization.